total neoadjuvant therapy
Phase 2Small molecule
total neoadjuvant therapy is one of 38 small molecule programs targeting Total Neoadjuvant Therapy. It is currently in Phase 2.
2
Indications
5
Total Trials
5
Active Trials
37
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
33 competitors in Rectal Cancer
#DrugCompanyPhaseTrials
1Eloxatin
TevaPhase 3
Xeloda
EEngelhard Arzneimittel GmbH & Co.KG
Phase 3
Adrucil
EElorac, Inc.
Phase 3
Wellcovorin
GGlaxo Dba Glaxosmithkline
Phase 3
Capeox
GSKPhase 3
Keytruda
Merck & Co.Phase 2
Stivarga
BayerPhase 2
Tukysa
PfizerPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
PD-1
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Total Neoadjuvant Therapy2 trials
Patients With Locally Advanced Rectal Cancer1 trial
GEMCAD-REVEAL STUDY - Circulating Tumor DNA as a Predictor of Relapse in Patients With Locally Advanced Rectal Cancer.
Active, not recruiting·GGrupo Espanol Multidisciplinario del Cancer Digestivo··NCT05674422·120 enrolled
Locally-advanced Rectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for total neoadjuvant therapy. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- SSt. James's Hospital, Ireland